Indications and pitfalls of immunohistochemistry in head and neck cancer |
| |
| Authors: | Décio de Natale Caly Acklei Viana Abrão Rapoport Rogério Aparecido Dedivitis Otávio Alberto Curioni Cláudio Roberto Cernea Lenine Garcia Brandão |
| |
| Affiliation: | PhD in Pathology from A.C. Camargo Hospital, São Paulo (Pathologist at the Heliópolis Hospital, São Paulo);Resident Physician in the Department of Head and Neck Surgery and Otorhinolaryngology at the Heliópolis Hospital, São Paulo;Associate Professor in the Department of Surgery at the Medical School of the University of São Paulo (Technical Director in the Department of Health at the Heliópolis Hospital, São Paulo);Associate Professor. Supervisor of the Larynx Group in the Department of Head and Neck Surgery of the University Hospital of the Medical School of the University of São Paulo (MD);PhD in Pathology from the Medical School of the University of São Paulo (Head of the Department of Head and Neck Surgery and Otorhinolaryngology at the Heliópolis Hospital, São Paulo);Associate Professor in the Department of Head and Neck Surgery at the Medical School of the University of São Paulo, São Paulo;Professor in the Department of Head and Neck Surgery at the Medical School of the University of São Paulo, São Paulo. Department of Head and Neck Surgery and Otorhinolaryngology at the Heliópolis Hospital, São Paulo and Department of Head and Neck Surgery at the Medical School of the University of São Paulo, São Paulo |
| |
| Abstract: | Immunohistochemistry (IHC) has been employed in the differential diagnosis of tumors.ObjectiveTo assess the use of IHC in cases of head and neck tumor.MethodThis is a retrospective study of the cases included in the Cancer Registry of the institution.ResultsIHC was used in 76 (11%) of 704 pathology tests. Most cases were carcinomas (85.80%), and 83.66% of them were squamous cell carcinomas. All tests were done with diagnostic purposes. The most frequently used antibodies were 34BE12 (37.18%), AE1/AE3 (35.9%), 35BH11 (28.21%), CD45 (25.64%), CD20 (24.36%), CD30 (24.36%), CK7 (23.08%) and CD3 (23.08%).ConclusionsIHC was used in 10.67% of the head and neck tumor cases submitted to pathology testing, mostly for carcinoma (5.26%). In the determination of squamous cell carcinoma, IHC accounted for 18.42% of all tumors. |
| |
| Keywords: | carcinoma, squamous cell head and neck neoplasms immunohistochemistry lymphoma sarcoma |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
